The 1st International standard for transforming growth factor-尾3 (TGF-尾3)

详细信息	查看全文 | 推荐本文 |

• 作者：Meenu Wadhwa^a ; ^{Meenu.Wadhwa@nibsc.hpa.org.uk} ; Paula Dilger^a ; Michelle Hamill^b ; David Bending^c ; Sarah Gibbs^d ; Guoping Wu^e ; Jo Read^f ; Tony Wyss-Coray^g ; Hui Zhang^g ; John Little^h ; Katherine M. Getliffe^h ; Gao Kaiⁱ ; Weihong Wang^j ; David Bender^j ; Chris Bird^a ; Alan B. Heath^b ; Anne Cooke^d ; Robin Thorpe^a
• 关键词：Transforming growth factor-尾3 ; standardization ; 1st International standard ; Potency ; Bioassay ; Th17 ; Treg
• 刊名：Journal of Immunological Methods
• 出版年：2012
• 期刊代码：57_00221759
• 类别：imm
• 出版时间：29 June, 2012
• 卷：380
• 期：1-2
• 页码：1-9
• 文件大小：861 K

摘要

One candidate preparation of human sequence recombinant transforming growth factor-尾3 (TGF-尾3) was formulated and lyophilized at NIBSC prior to evaluation in a collaborative study for its suitability to serve as an international standard. The preparation was tested by 8 laboratories using in vitro bioassays and immunoassays. The candidate preparation 09/234 was judged suitable to serve as an international standard based on the data obtained for biological activity and stability. On the basis of the results reported here, the preparation coded 09/234 was established by the WHO Expert Committee on Biological Standardisation (ECBS) as the WHO 1st IS for human TGF-尾3 with an assigned value for TGF-尾3 activity of 19, 000 IU/ampoule.